መነሻ4507 • TYO
add
Shionogi & Co Ltd
የቀዳሚ መዝጊያ
¥2,059.00
የቀን ክልል
¥2,062.50 - ¥2,109.50
የዓመት ክልል
¥1,944.66 - ¥2,712.33
የገበያው አጠቃላይ ዋጋ
1.86 ት JPY
አማካይ መጠን
2.61 ሚ
የዋጋ/ገቢ ምጥጥን
11.59
የትርፍ ክፍያ
2.71%
ዋና ልውውጥ
TYO
የገበያ ዜና
ፋይናንስ
የገቢ መግለጫ
ገቢ
የተጣራ ገቢ
(JPY) | ሴፕቴ 2024info | ከዓመት ዓመት ለውጥ |
---|---|---|
ገቢ | 116.38 ቢ | -4.00% |
የሥራ ወጪ | 52.93 ቢ | -3.66% |
የተጣራ ገቢ | 52.50 ቢ | 9.30% |
የተጣራ የትርፍ ክልል | 45.11 | 13.86% |
ገቢ በሼር | — | — |
EBITDA | 53.13 ቢ | -5.14% |
ውጤታማ የግብር ተመን | 8.28% | — |
ቀሪ ሒሳብ ሉሆች
አጠቃላይ ንብረቶች
አጠቃላይ ተጠያቂነቶች
(JPY) | ሴፕቴ 2024info | ከዓመት ዓመት ለውጥ |
---|---|---|
ጥሬ ገንዘብና የአጭር ጊዜ መዋዕለ ንዋይ | 303.40 ቢ | 20.22% |
አጠቃላይ ንብረቶች | 1.46 ት | 3.34% |
አጠቃላይ ተጠያቂነቶች | 145.93 ቢ | -18.09% |
አጠቃላይ እሴት | 1.31 ት | — |
የሼሮቹ ብዛት | 850.69 ሚ | — |
የገበያ ዋጋ እና የተገለጸ ዋጋ | 1.23 | — |
የእሴቶች ተመላሽ | 8.22% | — |
የካፒታል ተመላሽ | 9.10% | — |
የገንዘብ ፍሰት
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ
(JPY) | ሴፕቴ 2024info | ከዓመት ዓመት ለውጥ |
---|---|---|
የተጣራ ገቢ | 52.50 ቢ | 9.30% |
ከክወናዎች የተገኘ ጥሬ ገንዘብ | 45.30 ቢ | 220.14% |
ገንዘብ ከኢንቨስትመንት | -17.63 ቢ | 47.30% |
ገንዘብ ከፋይናንስ | -1.11 ቢ | 94.50% |
የተጣራ ዝርዝር ገንዘብ በጥሬ ገንዘብ | 21.45 ቢ | 158.43% |
ነፃ የገንዘብ ፍሰት | 8.02 ቢ | 135.46% |
ስለ
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
ዋና ሥራ አስፈጻሚ
የተመሰረተው
1878
ዋና መሥሪያ ቤት
ድህረገፅ
ሠራተኞች
4,959